Respiratory Infections

The development of BNT162 is based on BioNTech’s mRNA platform; the vaccine will then be produced using Pfizer’s vaccine manufacturing capacities.

New data shows the ChAdOx1 nCoV-19 vaccine candidate induces T cell response within 14 days, and antibody response within 28 days.

Quest Diagnostics will now able to efficiently test larger groups of specimen among persons from low-coronavirus risk areas.

Contracting influenza increased the risk for invasive pneumococcal disease in a study conducted across 3 countries.

Perspective on how the anticoagulant could progress to human trials and potentially, marketing use for coronavirus prevention.

Asymptomatic and presymptomatic cases of COVID-19 create challenges for identifying and combating the spread of the virus in detention facilities.

A discussion with an RPI investigator after promising early findings.

A modeling study from Imperial College shows the COVID-19 pandemic may have significant effect on mortality among other infectious disease patients.

West and Central African nations have been developing infrastructure to combat ebola, malaria, malnutrition, and more.

A modeling study from Imperial College shows the COVID-19 pandemic may require balancing with other infectious disease priorities.

Tens of thousands of patients were prescribed the anti-malarial drugs in the early weeks of the pandemic, a statistic that concerns public health officials.

Heparin may lower the odds of SARS-CoV-2 infection, according to investigators from the Rensselaer Polytechnic Institute.

New study findings shed light on the positive effects of baloxavir for preventing influenza spread in household settings.

Following an outbreak of both COVID-19 and H1N1 influenza, Parisian hospital admissions for Kawasaki disease increased.

The mRNA-1273 vaccine candidate from Moderna will progress to a phase 3 trial in adults later this summer.

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

Efforts to develop a COVID-19 vaccine must not skip important steps during clinical evaluation, experts explain.

Findings were announced during the special COVID-19 sessions of the virtual 23rd International AIDS Conference.

Over 200 scientists issued alert to medical community that COVID-19 is transmissible over longer distances via smaller aerosolized droplets.

Despite being within the age group at highest risk for severe SARS-CoV-2 infection, a recent survey suggests that the population is not inherently more willing to socially isolate.

How the inflammatory-based syndrome is affecting US children during the COVID-19 pandemic.

A discussion on how the pediatric inflammatory syndrome has begun to affect the US months into the pandemic.

A discussion with a Yale expert on what new CDC data shows.

Judith Feinberg, MD, FIDSA, describes ongoing investigation into the immune response from COVID-19.

A brief overview of our top stories.

Jonathan Spero, MD, discusses workplace safety in the time of SARS-CoV-2.

Recent concerns have been raised about a spike protein mutation in SARS-CoV-2. Are these fears grounded?

New recommendations are intended to aid biomedical firms in achieving licensure of a safe and effective vaccine.

Judith Feinberg, MD, FIDSA, describes surprising outcomes in many COVID-19 cases among people living with HIV.